Immuneering (IMRX) Competitors $1.24 -0.05 (-3.88%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.27 +0.03 (+2.42%) As of 05/2/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. ANNX, OCGN, ITOS, YMAB, GOSS, DMAC, IVA, MDWD, ELDN, and CRDFShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Annexon (ANNX), Ocugen (OCGN), iTeos Therapeutics (ITOS), Y-mAbs Therapeutics (YMAB), Gossamer Bio (GOSS), DiaMedica Therapeutics (DMAC), Inventiva (IVA), MediWound (MDWD), Eledon Pharmaceuticals (ELDN), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Annexon Ocugen iTeos Therapeutics Y-mAbs Therapeutics Gossamer Bio DiaMedica Therapeutics Inventiva MediWound Eledon Pharmaceuticals Cardiff Oncology Immuneering (NASDAQ:IMRX) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Which has stronger valuation and earnings, IMRX or ANNX? Immuneering has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K139.45-$53.47M-$2.03-0.61AnnexonN/AN/A-$134.24M-$1.02-1.93 Do institutionals and insiders hold more shares of IMRX or ANNX? 67.7% of Immuneering shares are held by institutional investors. 25.0% of Immuneering shares are held by insiders. Comparatively, 12.7% of Annexon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate IMRX or ANNX? Immuneering presently has a consensus price target of $12.50, indicating a potential upside of 908.06%. Annexon has a consensus price target of $18.67, indicating a potential upside of 847.55%. Given Immuneering's higher possible upside, equities analysts plainly believe Immuneering is more favorable than Annexon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Annexon 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IMRX or ANNX? In the previous week, Immuneering had 3 more articles in the media than Annexon. MarketBeat recorded 3 mentions for Immuneering and 0 mentions for Annexon. Annexon's average media sentiment score of 1.67 beat Immuneering's score of 1.18 indicating that Annexon is being referred to more favorably in the news media. Company Overall Sentiment Immuneering Positive Annexon Very Positive Which has more risk and volatility, IMRX or ANNX? Immuneering has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Does the MarketBeat Community favor IMRX or ANNX? Annexon received 19 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 77.46% of users gave Annexon an outperform vote while only 69.23% of users gave Immuneering an outperform vote. CompanyUnderperformOutperformImmuneeringOutperform Votes3669.23% Underperform Votes1630.77% AnnexonOutperform Votes5577.46% Underperform Votes1622.54% Is IMRX or ANNX more profitable? Annexon's return on equity of -38.99% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -79.19% -69.08% Annexon N/A -38.99%-33.90% SummaryAnnexon beats Immuneering on 9 of the 16 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.62M$6.85B$5.55B$8.02BDividend YieldN/A2.97%5.09%4.23%P/E Ratio-0.637.4422.6918.83Price / Sales139.45257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book0.406.576.794.33Net Income-$53.47M$143.14M$3.22B$247.97M7 Day Performance-14.48%3.35%3.33%3.16%1 Month Performance-17.88%10.29%6.89%8.10%1 Year Performance-24.39%-3.45%16.09%4.99% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.7744 of 5 stars$1.24-3.9%$12.50+908.1%-20.5%$44.62M$320,000.00-0.6360Upcoming EarningsShort Interest ↓News CoveragePositive NewsANNXAnnexon2.0797 of 5 stars$1.89+0.5%$18.67+887.7%-57.7%$207.35MN/A-1.8060Positive NewsGap UpOCGNOcugen1.0279 of 5 stars$0.71-1.3%$6.33+792.0%-42.0%$207.33M$4.06M-3.9480News CoverageITOSiTeos Therapeutics2.1027 of 5 stars$7.07-3.8%$25.75+264.2%-32.4%$205.87M$35M-2.2490Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageYMABY-mAbs Therapeutics3.8477 of 5 stars$4.23+3.2%$17.40+311.3%-74.4%$205.29M$87.69M-7.83150Upcoming EarningsShort Interest ↓News CoverageGOSSGossamer Bio4.051 of 5 stars$0.88-8.5%$7.50+755.8%+53.0%$199.14M$114.70M-2.74180Upcoming EarningsNews CoverageDMACDiaMedica Therapeutics1.6138 of 5 stars$4.64+14.9%$8.00+72.4%+60.8%$198.85MN/A-8.2920Upcoming EarningsNews CoverageHigh Trading VolumeIVAInventiva1.7854 of 5 stars$3.78-2.7%$10.40+174.8%+5.6%$198.57M$9.20M0.00100Gap UpMDWDMediWound1.4506 of 5 stars$18.29+1.2%$31.33+71.3%-8.4%$197.68M$20.22M-6.3180Analyst ForecastNews CoverageELDNEledon Pharmaceuticals2.2446 of 5 stars$3.28+1.2%$12.50+281.1%+43.9%$196.41MN/A-1.6310Upcoming EarningsShort Interest ↑News CoverageCRDFCardiff Oncology1.4583 of 5 stars$2.95+2.4%$11.67+295.5%-37.1%$196.25M$683,000.00-3.1420News Coverage Related Companies and Tools Related Companies ANNX Alternatives OCGN Alternatives ITOS Alternatives YMAB Alternatives GOSS Alternatives DMAC Alternatives IVA Alternatives MDWD Alternatives ELDN Alternatives CRDF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMRX Stock Free IMRX Stock Alerts